Gore has announced the first patient enrolment in its post-market European registry for the Gore TAG Conformable Thoracic Stent Graft with Active Control System, following its recent European launch in July 2017. The thoracic endovascular aortic repair (TEVAR) device is the first to feature a new delivery system that provides the physician with controlled, staged deployment.
Mercator MedSystems has announced completion of enrolment in the company’s LIMBO-ATX (Lower-limb adventitial infusion of dexamethasone via Bullfrog to reduce occurrence of restenosis after atherectomy-based revascularization) clinical trial. The LIMBO-ATX trial was designed to use Mercator’s proprietary Bullfrog micro-infusion catheter to test a new treatment strategy to potentially improve blood flow and decrease repeat revascularisation procedures in below-the-knee critical limb ischaemia.
An innovative, investigational treatment approach is showing the potential to address an important, unresolved problem encountered by patients with kidney failure on dialysis. At the recent annual meeting of the American Society of Nephrology (ASN), Vascular Therapies presented preliminary results relating to analysis of the first 18 (open-label) patients from its US phase III study. The study is testing the effect of the sirolimus-eluting collagen implant on arteriovenous fistula outcomes. The results suggest this investigational treatment approach may reduce a patient’s dependence on the extended use of catheters.
Percutaneous closure of large-bore arterial access sites using the Perclose ProGlide suture-mediated closure device (Abbott Vascular) is associated with significantly lower rates of blood transfusions, infections, mortality and length of hospital stay, compared with surgical cutdown in a real-world setting, according to new data presented at the Vascular Interventional Advances 2017 conference (VIVA; 11–14 September, Las Vegas, USA).
At the European Society for Vascular Surgery (ESVS) meeting (19–22 September, Lyon, France), Vascular News spoke to Florian Dick (University of Bern, Bern, Switzerland) about the new Global Vascular Guidelines for chronic limb-threatening ischaemia, which were presented to delegates as part of the scientific sessions. Dick told Vascular News about the main message behind the guidelines, and how they will form a framework around which the evidence base can grow. The guidelines are expected to be published online in the first quarter of 2018.
Philips has announced the results of an independent two-year study on clinicians’ use of Azurion, the company’s image-guided therapy platform, at St. Antonius Hospital. The study finds that use of Azurion by clinicians in the hospital resulted in significant time savings and higher employee satisfaction.
Cagent Vascular has announced the issuance of its CE marking for the Serranator percutaneous transluminal angioplasty (PTA) serration balloon catheter. Cagent Vascular has also achieved its ISO 13485 Certification. The Serranator is one of a family of peripheral artery disease (PAD) technologies which incorporates proprietary serration technology to an angioplasty balloon.
A 53-year-old woman with a complex aortic malfunction causing a bulging blood vessel attended University Hospital Mainz (Mainz, Germany), having been rejected by several other hospitals due to the risky nature of her required surgery. Bernhard Dorweiler— head of the Department of Vascular Surgery at the hospital—utilised an emerging technology to assist in the careful planning of the surgery.
Positive single-centre 24-month results from Intact Vascular’s TOBA (Tack optimised balloon angioplasty) clinical study were presented at the 2017 VEITHsymposium 2017 (14–18 November, New York City, USA) by Christian Wissgott (Westküstenklinikum Heide, Heide, Germany).
Vascular Flow Technologies (VFT) has announced the successful conclusion of a strategic intellectual property out-licencing agreement with Biovic Sdn bhd.
Bayer and its cooperation partner Janssen Research & Development have announced two publications of further data from the Phase III COMPASS study in The Lancet, one in patients with peripheral artery disease (PAD) and the other in patients with coronary artery disease (CAD).
Getinge has installed the 1,000th hybrid operating room (OR) worldwide. West Virginia University (WVU) Heart and Vascular Institute, in Morgantown, USA, has installed three new, state-of-the-art hybrid ORs. Designed for patients requiring vascular or structural heart procedures, Hybrid ORs combine a traditional operating room with a catheterisation lab and imaging suite.
InspireMD has announced it has signed Diverse Devices as its exclusive distributor for Australia and New Zealand, and has signed Do Gia Production and Trading JSC as its exclusive distributor in Vietnam. The company’s product line includes the Cguard embolic prevention system (EPS).
Following a fenestrated endovascular aneurysm repair (FEVAR), the infrarenal aortic neck often continues to dilate. At the 2017 VEITHsymposium, Benjamin Starnes (University of Washington, Seattle, USA) suggested that such dilation is harmful when observed in standard EVAR practised outside instructions for use (IFU) or in association with a hostile neck. However, Starnes said that aortic neck dilation is harmless when observed with FEVAR, and that “less device oversizing may be acceptable given long seal zone lengths”.
The use of surgical simulators is important to assess competence, plan complex cases and develop skills, but they “do not replace clinical and surgical experience,” according to José Fernandes e Fernandes (Lisbon Academic Medical Centre and Lisbon Cardiovascular Institute, Lisbon, Portugal), who spoke at the 2017 VEITHsymposium (14–18 November, New York, USA).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos